ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExpanded RAS analysis is essential for guiding targeted therapy in metastatic colorectal cancer (mCRC), as RAS mutations predicts resistance to anti-EGFR agents. This study aimed to evaluate the plasma RAS mutation status using liquid biopsy at disease progression and to assess the prognostic significance of RAS mutation clearance.
methodsIn this prospective study, 58 patients with mCRC harboring RAS mutations in baseline tumor tissue were enrolled. All patients experienced disease progression following first-line chemotherapy combined with bevacizumab. Plasma samples collected at progression were analyzed using the Idylla™ PCR-based system for detection of KRAS and NRAS mutations in circulating tumor DNA (ctDNA). Survival outcomes were estimated using the Kaplan-Meier method and compared with the log-rank test.
resultsThe median age was 60 years (IQR 35-83), and 60.3% of patients were male. The primary tumors were left sided in 81.0% of cases. At baseline, 94.8% of the patients had KRAS and 5.2% had NRAS mutations. At progression, ctDNA analysis revealed KRAS mutations in 56.9% and NRAS mutations in 3.4% of patients, while 39.7% showed no detectable RAS mutation in plasma. No significant differences in clinicopathological characteristics were observed between patients with persistent RAS mutations and those with RAS clearance. However, overall survival was significantly longer in patients with RAS wild-type conversion compared to those with persistent RAS mutations (44.3 vs. 19.6 months, p = 0.002).
conclusionThis study demonstrated that dynamic changes in plasma RAS mutation status may occur during disease progression in patients with mCRC, potentially reflecting tumor clonal evolution. The observed survival advantage in patients with RAS mutation clearance suggests potential prognostic relevance. Reassessment of RAS status using liquid biopsy at disease progression may provide clinically relevant information; however, these findings should be considered exploratory and require prospective validation in larger cohorts.
Indexed as
Identifiers
42340652What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.